Profil
Lois A. Chandler is currently the Chief Operating Officer at Taxus Cardium Pharmaceuticals Group, Inc. She previously worked as the Vice President-Product Development at Activation Therapeutics, Inc. from 2006 to 2019.
Dr. Chandler completed her undergraduate degree at Stanford University and holds a doctorate from the University of Southern California.
Aktive Positionen von Lois Chandler
| Unternehmen | Position | Beginn |
|---|---|---|
Taxus Cardium Pharmaceuticals Group, Inc.
Taxus Cardium Pharmaceuticals Group, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes angiogenic gene therapy products for cardiovascular disease | Geschäftsführer | 01.07.2019 |
Ehemalige bekannte Positionen von Lois Chandler
| Unternehmen | Position | Ende |
|---|---|---|
Activation Therapeutics, Inc.
Activation Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops late-stage clinical and commercial development of regenerative medicine therapeutics | Corporate Officer/Principal | 01.01.2019 |
Ausbildung von Lois Chandler
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Southern California
University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Taxus Cardium Pharmaceuticals Group, Inc.
Taxus Cardium Pharmaceuticals Group, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes angiogenic gene therapy products for cardiovascular disease | Health Technology |
Activation Therapeutics, Inc.
Activation Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops late-stage clinical and commercial development of regenerative medicine therapeutics | Health Technology |
















